<DOC>
	<DOC>NCT01603277</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.</brief_summary>
	<brief_title>Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key A diagnosis of asthma established for at least 2 years Symptomatic asthma as defined by the Juniper Asthma Control Questionnaire Symptomatic asthma despite stable treatment with inhaled corticosteroids fluticasone or budesonide, or other corticosteroids, for at least 12 weeks Currently receiving inhaled longacting beta agonist (LABA) or previously documented LABA intolerability or lack of responsiveness At least 2 exacerbations (no more than 6) in the previous 12 months that required systemic corticosteroids or at least a doubling of daily oral dose Key Acute asthma worsening (requiring emergency room visit, hospitalization, urgent care, physician visit, or change in asthma medications) or lower respiratory tract infection requiring the use of antibiotics, within 4 weeks prior to Screening Visit. History of lifethreatening asthma with admission to the intensive care unit requiring the use of mechanical ventilation within the past 12 months Use of any immunosuppressive or immunomodulatory agents within 12 weeks or an investigational agent within 4 weeks prior to Screening Visit History of any cardiovascular, neurological, hepatic, or renal condition History of smoking within the past 12 months</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Moderate-to-Severe Asthma</keyword>
</DOC>